This trial is evaluating whether tinzaparin will improve 2 primary outcomes, 9 secondary outcomes, and 1 other outcome in patients with Postthrombotic Syndrome. Measurement will happen over the course of 10 days post randomization.
This trial requires 60 total participants across 2 different treatment groups
This trial involves 2 different treatments. Tinzaparin is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
In our case the patient underwent thrombectomy in the right femoral artery without any complications. The thrombus was very small, and it would be impossible to cure the patient with this tool. Thus, we believe that thrombal aspiration should be only a complementary thrombectomy procedure in case of complete thrombectomy or when the lumen of the blood vessel is too narrow for the thrombus to pass through.
More than a year in a million US adolescents and adults have undergone surgery for nonfatal venous thromboembolism. More than 3.4 million, or about 1.4 per 10 000 population, had a venous thromboembolism diagnosed in the 12 months preceding the survey.
Thrombus is the formation of a blood clot within a blood vessel. Blood clots can arise either from a break in the vessel wall (intraluminal thrombus) or within the lumen of a blood vessel (extraluminal thrombus). When blood clots develop in the coronary artery, they form, and they can form either within the artery supplying a tissue and thus within (intra-arterial thrombus) or outside (extra-arterial thrombus) the vessel.
Signs of thrombosis should trigger high alertness for DVT. Abdominal pain is a new feature as a sign of DVT and was significantly related to a long latency to diagnosis. It was the most common symptom associated with thrombus. Although DVT is highly prevalent in patients with known risk factors, clinicians should be alert if any patients have new or increased signs/symptoms of DVT such as pain at the site of the clot, or fever.
Atherosclerotic plaque rupture and subsequent clot formation are the most common modes of embolization. While a variety of modalities and treatments are available, they are still limited by a paucity of evidence and a lack of consensus due to the complexity involved in the treatment of this disease.
Thrombus occurs because a clotting protein does not attach itself to a blood vessel wall. This happens when blood vessels are blocked by an embolus or other extrusion of substances. A clot is then formed and the vessel blocked by arterial thrombi. This can occur in the artery supplying the thigh or below the knee. The diagnosis is most likely to be correct when it is the result of a ruptured atheroma on an artery. In rare cases, the arterial blockage occurs in the vein. The diagnosis is typically made after a blockage develops in the thigh, calf or below the knee, and often the diagnosis is made during an examination of the leg.
There are no studies involving tinzaparin for PE management, but studies do exist that mention tinzaparin in other, unrelated disorders. However, no other studies exist where tinzaparin has been studied as a single agent for PE or antifactor Xa in general. The absence of controlled studies on tinzaparin in PE and antifactor Xa in general is most likely because the results from clinical trials are often not published. Another possibility is that because a patient would be taking another therapeutic agent at a time when the study of tinzaparin is being performed, it would be difficult to know if the effects of tinzaparin were more profound compared with that of the other drug than they actually were.
For patients with a history of thromboembolic events, a balanced diet, weight stability, cessation of tobacco use, appropriate exercise, and anticoagulant therapy remain the standard of care. Although these modalities are effective, they are often inappropriate and costly, and have a number of limitations and complications. Further research is necessary to determine what treatment provides better outcomes or improves quality of life for these patients.
Tinzaparin appears to be safe and may have a clinical benefit for patients with thrombin-induced thrombotic thrombocytopenia. A randomised clinical trial is required to further assess the efficacy and safety of tinzaparin after a major bleeding episode. A meta-analysis of three recent trials of tinzaparin showed no significant difference in bleeding or blood product transfusion between low-molecular-weight heparin and tinzaparin.
There is still insufficient evidence for the use of tinzaparin for preventing thromboembolic complications related to the post-thrombotic syndrome. Based on evidence from controlled studies with other anticoagulants, there is a good rationale for the use of tinzaparin in patients with symptomatic post-thrombotic syndrome, but there is no evidence for the efficacy of tinzaparin in an anticoagulant-uncontrolled postthrombotic syndrome cohort.
Thrombocytopenia (>40×109 cells/L) and pain/burning at site of injection were the most frequent adverse events observed through post-marketing surveillance. Thrombocytopenia and pain/burning at site of injection were more common with tinzaparin than with the newer (non-peptide) thromboprophylaxis agents.